Difference between revisions of "Tofacitinib (Xeljanz)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=759505 NCI Drug Dictionary]: An orally available inhibitor of Janus kinases (...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
||
| Line 10: | Line 10: | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Oral | + | [[Category:Oral medications]] |
[[Category:JAK inhibitors]] | [[Category:JAK inhibitors]] | ||
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 16:57, 25 July 2017
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases.
History of changes in FDA indication
Note that this drug does not have an oncology-specific label at this time.
- 11/6/2012: Initial FDA approval for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
Also known as
CP-690550, tasocitinib